Differential effects or rivastigmine, galantamine and donepezil on behavioral and psychological symptoms in patients with Alzheimer's disease: 18-month, randomized, open-label trial

Primary Care and Community Psychiatry

Volumn 10, Issue 3, 2005, Pages 95-102

  Cumbo, Eduardo ^a  

^a ASS N 2   (Italy)

Author keywords

Alzheimers' disease; Behavioral and Phychological Symptoms of Dementia; Cholinesterase inhibitors

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE; SULPIRIDE;

AGED; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSION; DEPRESSION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MOOD DISORDER; NAUSEA; PARANOIA; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESSNESS; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; VOMITING; WEIGHT REDUCTION;

EID: 33644826545     PISSN: 17468841     EISSN: 14734885     Source Type: Journal    
DOI: 10.1185/135525705X40436     Document Type: Article

References (31)

1. Leroi I, Volgari A, Breitner JC, Lykestos CG. The epidemiology of psychosis in dementia. Am J Geriatr Psychiatry 2003; 111:83-91
2. Lykestos CE, Lopez O, Jones B, Fitzpatrick AL, Breitner J, De Kosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. JAMA 2002; 288:1475-83
3. Teri L: Behaviour and carer burden: behavioural problems in patients with Alzheimer's disease and its association with carer distress. Alz Dis Assoc Disord 1997; 11: 35-8
4. Grossberg GT. The ABC of Alzheimer's disease: behavioural symptoms and their treatment. Int Psychogeriatrics 2002; 14 (Suppl 1):S27-S49
5. Murman DL, Chen Q, Powell MC, Colenda CC. The incremental costs associated with behavioral symptoms in Alzheimer's disease. Neurology 2001; 56 (Suppl 3):A160-1
6. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology 1996; 47: 876-83
7. Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology 1998; 51 Suppl 1: S18-29
8. Xie W, Stribley JA, Chatonnet A, Wailder PJ, Rizzino A, McComb RD, Taylor P, Hinrichs SH, Lockridge O. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther 2000; 293:896-902
9. Darvesh S, Hopkins DA, Geula C. Neurobiology of butyrylcholinesterase. 2003; 4: 131-8
10. Kaufer D. Effect of tacrine on behavioural symptoms in Alzheimer's disease and related dementias: an open-label study. J Geriatr Psychiatr Neurol 1996; 9:1-6
11. Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioural disturbances in Alzheimer's disease. Neuropsychiatr Neuropsychol Behav Neurol 1993; 6:223-30
12. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis and non-cognitive behavioural problems in Alzheimer's disease. Arch Neurol 1997; 54:836-40
13. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 1998; 50:1214-21
14. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer's disease. Arch Neurol 1999; 56:1388-93
15. Cummings JL, Donohue JA, Brooks RL. The relationship between donepezil and behavioural disturbances in patients with Alzheimer's disease. Am J Geriatr Psychiatry 2000; 8:134-40
16. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled, international study. Lancet 2000; 356:2031-36
17. Bullock R, Moulias R, Steinwachs KC, Cicin-Sain A, Spiegel R. Effects of rivastigmine on behavioral symptoms in nursing home patients with Alzheimer's disease. Int Psychogeriatr 2001; 13 (Suppl 2):P248
18. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld FCP, Ding C. The Galantamine USA-10 Study Group: A 5-month, randomized, placebo-controlled trial of galantamine in Alzheimer's disease. Neurology 2000; 54:2269-76
19. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P and the Donepezil MSD. A study group: Benefits of donepezil on global function, behaviour, cognition and ADLs in patients with moderate to severe Alzheimer's disease. Neurology 2000; 54 (Sup.3): A469
20. Etemad B. Behavioral and cognitive benefits of rivastigmine in nursing home patients with Alzheimer's disease and related dementias: A 26-week follow-up. Int Psycgogeriatr 2001; 13 (Suppl 2): P-246
21. Trinh H, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer's disease. JAMA 2003; 289:210-16
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ARDRA Work Goup under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44
23. Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bull 2005; 64: 519-24
24. Cummings JL, Mega M, Gray K, Rosemberg-Thompson S, Carusi DA, Gornbei J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-14
25. Kaufer DL, Cummings JL, Christine D, Bray T, Castellon S, Masterman MD, McMillian A, Ketchel P. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory Caregiver Distress Scale. J Am Geriatr Soc 1998; 46:210-15
26. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgatos A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatr 1987; 48:9-15
27. Holsboer-Trachsler E, Hatzinger M, Stohler R, Hemmeter U, Gray J, Muller J, Kocher R, Spiegel R. Effects of the novel acetylcholinesterase inhibitor SDZ ENA 713 on sleep in man. Neuropsychopharmacology 1993; 8:87-92
28. Schredl M, Weber B, Braus D, Heuser I. The effect of rivastigmine on sleep in elderly healthy subjects. Exp Gerontol 2000; 35: 243-9
29. Finkel SI. Effects of Rivastigmine on Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease. Clin Ther 2004; 26: 980-90
30. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 243-9
31. Aupperle PM, Koumaras B, Chen M, Rabinowicz A, Mirski D. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin 2004; 20: 1605-12